GSK Wellbutrin XL Has Captured Half Of Total Bupropion Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Wellbutrin XL holds 49.6% share of new scripts written for Wellbutrin brand and generic equivalents, Biovail reports. Biovail revenues from product jump to $79.1 mil. in quarter, helped by move up to next tier of pricing in supply agreement with GSK.
You may also be interested in...
Impax/Teva Launch Wellbutrin SR Generic As Andrx Relinquishes Exclusivity
The 150 mg Impax/Teva product is following Eon's and Watson's 100 mg generics to the market. Andrx will receive a share of the profits.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.